United Therapeutics (NASDAQ: UTHR) — Perfil da empresa, notícias e dados financeiros
United Therapeutics develops innovative therapies for chronic diseases, focusing on pulmonary arterial hypertension and patient care.
United Therapeutics
United Therapeutics is a biotechnology company focused on the development and commercialization of pharmaceutical products and organ manufacturing technologies for patients with chronic and life-threatening conditions, particularly pulmonary arterial hypertension. Headquartered in Silver Spring, Maryland, with key operations in Research Triangle Park, North Carolina, the company commercializes prostacyclin analogs and other targeted therapies designed to improve exercise capacity and delay disease progression. In addition to its approved pharmaceutical portfolio, the company advances regenerative medicine and organ transplantation initiatives, including ex-vivo lung perfusion services and xenotransplantation research aimed at addressing the global shortage of donor organs for transplant recipients.
Resumo
Operações
Produtos e/ou serviços de United Therapeutics
- Inhaled Prostacyclin Therapies: Inhalation solution and dry powder formulations of treprostinil administered to treat pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, serving as a primary revenue generator by enhancing patient exercise tolerance and functional performance.
- Parenteral Prostacyclin Therapies: Continuous subcutaneous and intravenous infusions of treprostinil delivered via ambulatory pumps for patients with severe pulmonary arterial hypertension, providing continuous vascular dilation to reduce pulmonary arterial pressure and improve clinical outcomes.
- Oral Prostacyclin Therapies: Extended-release oral tablets containing treprostinil prescribed for patients with pulmonary arterial hypertension, providing a convenient non-invasive administration route designed to improve exercise capacity and delay clinical disease progression.
- Pediatric Oncology Biologics: Monoclonal antibody therapies administered in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2, and isotretinoin for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior multi-agent therapy.
- Oral PDE-5 Inhibitor Therapies: Oral phosphodiesterase type 5 inhibitor formulations, including oral suspension and tablet products, prescribed to improve exercise ability in patients diagnosed with pulmonary arterial hypertension by promoting relaxation of pulmonary vascular smooth muscle.
- Organ Manufacturing and Xenotransplantation: Advanced biotechnology development programs involving ex-vivo lung perfusion, gene-edited porcine organ transplantation, and 3D bioprinting aimed at producing transplantable lungs, kidneys, and hearts to address end-stage organ failure and donor organ shortages.
equipe executiva do United Therapeutics
- Martine A. RothblattFounder, Chairman & CEO
- Michael I. BenkowitzPresident & COO
- James C. EdgemondCFO & Treasurer
- Paul A. MahonExecutive VP, General Counsel & Corporate Secretary
- Harrison SilversManager of Investor Relations
- Holly HobsonAssociate Vice President of Human Resources
- Patrick PoissonExecutive Vice President of Strategic Development
- Leigh PetersonExecutive Vice President of Product Development & Xenotransplantation
- Gil GoldenSenior VP & Chief Medical Officer
Últimas notícias sobre a United Therapeutics
United Therapeutics secures FDA clearance for SUMMIT trial
United StatesUnited Therapeutics wins Yutrepia patent ruling
United StatesUnited Therapeutics rises after patent ruling
United StatesUnited Therapeutics seeks IPF approval for Tyvaso
United StatesUnited Therapeutics highlights PAH trial data
United StatesUnited Therapeutics acquires Thymmune for $140 million
United States
Principais indicadores financeiros
Resultados divulgados pela United Therapeutics , em USD.
- Cap. de mercado
- 24,8 bi
- Receita (TTM)
- 3,2 bi
- P/L
- 22.0
- LPA (diluído, TTM)
- 26.5
- Dividend yield
- —
- Margem de lucro
- 38.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 3,2 bi | 1,5 bi | 1,3 bi | |
| 2,9 bi | 1,4 bi | 1,2 bi | |
| 2,3 bi | 1,2 bi | 984,8 mi | |
| 1,9 bi | 979,7 mi | 727,3 mi |